Destiny-breast01 nct03248492

Author: ehop

August undefined, 2024

WebDec 11, 2024 · Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrialsg. ov number, NCT03248492). ABSTRACT Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer WebDec 23, 2024 · Efficacy was investigated in DESTINY-Breast01 (NCT03248492), a multicentre, single-arm trial enrolling 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies. Patients received fam-trastuzumab deruxtecan-nxki 5.4 mg/kg by intravenous infusion …

HER2+ Breast Cancer Findings Presented at ESMO 2024

WebMar 30, 2024 · In DESTINY-Breast01 (NCT03248492) and DESTINY-Breast03 (NCT03529110), trastuzumab deruxtecan (T-DXd) demonstrated unprecedented activity in patients (pts) with HER2+ (immunohistochemistry 3 ... WebSep 1, 2024 · The DESTINY-Breast01 study is a clinical study in participants with a type of breast cancer called HER2-positive breast cancer. The participants in the study received a treatment called trastuzumab deruxtecan, also known as T-DXd. solid wood kitchen island tops

Exposure‐Response Relationships in Patients With HER2‐Positive ...

Web转移性乳腺癌试验背景. ds8201的疗效在destiny-breast01（nct03248492）研究中进行了评估，这是一项多中心、单臂的试验，纳入了184 ... Web2 days ago · The antitumor activity and tolerability of T-DXd was first shown in the phase 2 DESTINY-Breast01 trial (NCT03248492), and was confirmed by findings from the phase 3 DESTINY-Breast03 trial ... WebMay 28, 2024 · On the basis of findings of the phase 2 DESTINY-Breast01 trial (NCT03248492), T-DXd was approved for the treatment of adult pts with HER2+ unresectable or mBC who have received ≥2 prior anti-HER2–based regimens (US and Europe) or had prior chemotherapy and are refractory to or intolerant of standard … small and whitfield reviews

推进乳腺癌治疗，肿瘤专家对当前和新兴的HER2靶向药物的研究仍 …

WebOn the basis of findings of the phase 2 DESTINY-Breast01 trial (NCT03248492), T-DXd was approved for the treatment of adult pts with HER2+ unresectable or mBC who have received ≥2 prior anti-HER2–based regimens (US and Europe) or had prior chemotherapy and are refractory to or intolerant of standard treatments (Japan). WebJul 14, 2024 · The landmark phase 2 DESTINY-Breast01 trial (NCT03248492), showed that T-DXd had an objective response rate (ORR) of 61.4% and median progression-free survival (mPFS) of 19.4 months in patients with previously treated HER2+ advanced or metastatic breast cancer [2,3]. The trial allowed enrollment of patients with stable brain metastases, … solid wood kitchen microwave cabinetWebDESTINY-Breast01 (NCT03248492) is an open-label, international, multicenter, phase 2 registration study of T-DXd in subjects with centrally confirmed HER2-positive metastatic BC. Methods Part 1 of this 2-part study was performed in 2 stages (pharmacokinetics and dose finding; T-DXd 5.4, 6.4, 7.4 small and whitfield upcoming auction

"WebT-DXd has been approved for HER2-positive metastatic breast cancer and for HER2-positive metastatic gastric cancer. The approval in breast cancer was based on results from the DESTINY-Breast01 (U201; NCT03248492) and J101 (NCT02564900) trials. Here, we present dose justification for the approved 5.4 mg/kg every-3-weeks (Q3W) dose based … " - Destiny-breast01 nct03248492

Destiny-breast01 nct03248492

Program Guide – ASCO Meeting Program Guide

WebNov 8, 2024 · In the phase 2 DESTINY-Breast01 trial (NCT03248492), investigators reported a median progression-free survival (PFS) of 16.4 months among 184 heavily pretreated patients. Responses were observed in 112 patients (60.9%); the disease control rate was 97.3%. 2 Web在 DESTINY-Breast01和DS8201-A-J101研究(NCT02564900)中，对234名接受了至少一剂曲妥珠单抗重组冻干粉注射剂 5.4mg/kg的不可切除或转移性HER2阳性乳腺癌患者的汇总分析中评估了安全性。曲妥珠单抗重组冻干粉注射剂i最常见的不良反应(频率≥20%)为恶心、疲劳、呕吐、脱发 ...

Did you know?

WebNCT03248492 Other Study ID Numbers: DS8201-A-U201 2016-004986-18 ( EudraCT Number ) JapicCTI-173693(en) ( Registry Identifier: JapicCTI ) DESTINY-Breast01 ( Other Identifier: Daiichi Sankyo and AstraZeneca ) First Submitted: August 10, 2024: First Posted: August 14, 2024: Results First Submitted: January 17, 2024: Results First Posted: … WebDESTINY-Breast01 (NCT03248492) is an open-label, international, multicenter, phase 2 study of T-DXd in patients with HER2-positive MBC; it supported regulatory approval globally. Data from prior data cutoffs (primary: August 1, 2024; initial update: June 8, 2024) showed that patients receiving T-DXd had durable responses.

WebJul 14, 2024 · Pooling data from August 2015 to June 2024 (61 patients participated in phase 1 studies DS8201-A-J101 [NCT02564900], and DS8201-A-A104 [NCT03383692], and 184 patients were in the phase 2 DESTINY-Breast01 study [NCT03248492]), including this update from ASCO, indicated that ILD occurred in 15.5% of patients with HER2 … WebBackground: DESTINY-Breast01 (NCT03248492) is a phase II single-arm trial evaluating trastuzumab deruxtecan (T-DXd) in adults with human epidermal growth factor receptor 2-positive (HER2+) unresectable or metastatic breast cancer (u/mBC) who have received two or more prior anti-HER2 therapies. Objectives: Objectives were to explore approaches …

WebFeb 2, 2024 · (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.) Approximately 15 to 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). 1–3 The recommended first-line therapy for HER2-positive … WebDec 11, 2024 · (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.) ... DESTINY-Breast01 was a single-group study with a median follow-up of only 11 months. Study Design and Patients. In this randomized, double-blind, placebo …

WebJun 10, 2024 · On the basis of findings from J101, T‐DXd was further evaluated in the registrational phase II DESTINY‐Breast01 trial (U201; NCT03248492) in patients with HER2‐positive unresectable or metastatic breast cancer who had previously been treated with T‐DM1. 10 Patients enrolled in this trial were heavily pretreated, having received a …

WebAug 5, 2024 · In the DESTINY-Breast01 phase II trial (NCT03248492), T-DXd demonstrated high rates of durable responses in heavily pretreated patients with HER2-positive mBC, with a confirmed objective response rate of 62%, median duration of response of 18.2 months, and median progression-free survival of 19.4 months. In addition to efficacy, successful ... solid wood kitchen dining tablesWebDec 10, 2024 · “DESTINY-Breast02 confirms the favorable benefit-risk ratio of trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer.” The 12-month and 24-month PFS rates were 62.3% (95% CI, 57.0%-67.1%) and 42.2% (95% CI, 36.5%-47.8%) of patients who received trastuzumab deruxtecan. solid wood kitchen trolleyWebMay 24, 2024 · Finally, the DESTINY-Breast04 trial (NCT03734029) is investigating trastuzumab deruxtecan versus chemotherapy in patients with HER2-low expressing breast cancer that has spread or cannot be ... solid wood kitchen shelvesWebFeb 15, 2024 · Abstract. BackgroundTrastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) is an open-label, international, multicenter, phase 2 study of T-DXd in patients with HER2 positive … small and wideWebAug 14, 2024 · Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. solid wood kitchen island with granite topWebDec 2, 2024 · DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC).We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. solid wood lateral fileWebApr 30, 2024 · The safety of T-DXd was evaluated in a pooled analysis of 234 patients with HER2-positive breast cancer who received at least one dose of T-DXd 5.4 mg/kg in the DESTINY-Breast01 (NCT03248492), and in the phase 1 trial DS8201-A-J101 (NCT02564900) [9,10,22]. The most common adverse events (AE) (i.e., frequency … solid wood labyrinth game